Preclinical experiments suggest that PARP inhibitor treatment can potentiate the effect of chemotherapy or radiotherapy in soft tissue sarcomas, particularly with gene fusions EWSR1::FLI1 and EWSR1::ERG [26]. Here, EWSR1 is linked to soft tissue sarcoma.